- Home
- QS vs AAPG Comparison
QS vs AAPG Comparison
Compare QS & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- AAPG
- Stock Information
- Founded
- QS 2010
- AAPG 2009
- Country
- QS United States
- AAPG China
- Employees
- QS N/A
- AAPG N/A
- Industry
- QS Auto Parts:O.E.M.
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- AAPG Health Care
- Exchange
- QS Nasdaq
- AAPG Nasdaq
- Market Cap
- QS 4.5B
- AAPG 3.6B
- IPO Year
- QS N/A
- AAPG 2025
- Fundamental
- Price
- QS $15.93
- AAPG $39.38
- Analyst Decision
- QS Sell
- AAPG Buy
- Analyst Count
- QS 6
- AAPG 1
- Target Price
- QS $5.88
- AAPG N/A
- AVG Volume (30 Days)
- QS 51.9M
- AAPG 9.1K
- Earning Date
- QS 10-22-2025
- AAPG 11-06-2025
- Dividend Yield
- QS N/A
- AAPG N/A
- EPS Growth
- QS N/A
- AAPG N/A
- EPS
- QS N/A
- AAPG N/A
- Revenue
- QS N/A
- AAPG $54,524,554.00
- Revenue This Year
- QS N/A
- AAPG N/A
- Revenue Next Year
- QS N/A
- AAPG $368.64
- P/E Ratio
- QS N/A
- AAPG N/A
- Revenue Growth
- QS N/A
- AAPG N/A
- 52 Week Low
- QS $3.40
- AAPG $16.50
- 52 Week High
- QS $16.49
- AAPG $48.45
- Technical
- Relative Strength Index (RSI)
- QS 76.39
- AAPG 49.07
- Support Level
- QS $12.05
- AAPG $37.20
- Resistance Level
- QS $14.17
- AAPG $40.48
- Average True Range (ATR)
- QS 1.48
- AAPG 0.75
- MACD
- QS 0.32
- AAPG 0.20
- Stochastic Oscillator
- QS 91.49
- AAPG 67.07
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.